Core Insights - Medtronic plc is a global leader in healthcare technology, focusing on device-based medical therapies and services for various health conditions [1] Financial Performance - Medtronic is set to report its Q2 2026 earnings on November 18, with analysts expecting an EPS of $1.31, an increase from $1.26 in the previous year [2] - Quarterly revenue is anticipated to reach $8.85 billion, up from $8.40 billion a year earlier [2] - The company reported Q1 2026 earnings with an adjusted EPS of $1.26, exceeding the consensus estimate of $1.23, and revenues of $8.58 billion, surpassing the consensus of $8.38 billion [3] Growth Outlook - The CEO highlighted a consistent quarter of mid-single-digit organic revenue growth, driven by innovative product categories such as Pulsed Field Ablation and Transcatheter Valves [4] - Medtronic raised its full-year 2026 diluted non-GAAP EPS guidance to a new range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60 [4] Dividend Information - Medtronic's dividend yield stands at 2.98%, with a total dividend payout of $2.84 per share over the last 12 months [2] - To generate an income of $100 per month from dividends, an investment of approximately $40,268 is required, based on the current dividend yield [5][6]

Core Insights - Medtronic plc reported its first quarter fiscal 2026 financial results, achieving mid-single digit organic revenue growth for the 11th consecutive quarter, with expectations to accelerate growth in the second half of the fiscal year [1][2][3] Financial Performance - The company reported worldwide revenue of $8.578 billion, an increase of 8.4% as reported and 4.8% on an organic basis [3][4] - GAAP operating profit was $1.445 billion with an operating margin of 16.8%, reflecting a 13% increase and a 70 basis point improvement [3][4] - Non-GAAP operating profit was $2.016 billion with a margin of 23.6%, showing a 3% increase but an 80 basis point decrease [3][4] Earnings and Guidance - GAAP net income was $1.040 billion, with diluted earnings per share (EPS) at $0.81, remaining flat, while non-GAAP diluted EPS increased by 2% to $1.26 [4][8] - The company raised its FY26 EPS guidance to a range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60, and reiterated its organic revenue growth guidance of approximately 5% [7][8][9] Segment Performance - Cardiac Ablation Solutions revenue surged nearly 50%, with a 72% increase in the U.S. driven by pulsed field ablation products [4][5] - The Cardiovascular Portfolio generated $3.285 billion in revenue, a 9.3% increase as reported and 7.0% organic [5][19] - The Diabetes business reported revenue of $721 million, an increase of 11.5% as reported and 7.9% organic [5][19] International and U.S. Revenue - International revenue reached $4.354 billion, a 13.6% increase, while U.S. revenue was $4.224 billion, reflecting a 3.5% increase [22][19] - The Cardiovascular segment in the international market grew by 12.6%, with notable increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic categories [22][19] Operational Efficiency - The company is focused on improving efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth while increasing investments in R&D, sales, and marketing [9][8]